Targeted screening and treatment for latent tuberculosis infection using QuantiFERON®-TB Gold is cost-effective in Mexico

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 8, 2009, Pages 962-968

  Burgos, Jose L ^a,e   Kahn, J G ^b   Strathdee, S A ^a   Valencia Mendoza, A ^c   Bautista Arredondo, S ^c   Laniado Laborin, R ^d   Castaneda ^d   Deiss, R ^a   Garfein, R S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^d UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cost effectiveness; Latent tuberculosis infection; QuantiFERON; Screening

Indexed keywords

GOLD; ILLICIT DRUG; ISONIAZID;

ANALYTICAL EQUIPMENT; ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DRUG USE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INCOME; INFECTION PREVENTION; INFECTION RISK; LATENT TUBERCULOSIS INFECTION; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEXICO; MONEY; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SCREENING; SCREENING TEST; SENSITIVITY ANALYSIS; SEX WORKER; TUBERCULOSIS; UNITED STATES; WORKER;

COMORBIDITY; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; MARKOV CHAINS; MASS SCREENING; MEXICO; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; TUBERCULOSIS;

EID: 69149086470     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Baltussen R, Floyd K, Dye C. Achieving the millennium development goals for health: cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 2005; 331: 1364-1368. (Pubitemid 43773486)
2. Floyd K, Blanc L, Raviglione M, Lee J W. Resources required for global tuberculosis control. Science 2002; 295: 2040-2041. (Pubitemid 34229457)
3. Castellanos M. Health system reform and political will: do these interventions enable reduction in TB burden? 12th Annual Conference of the International Union Against Tuberculosis and Lung Disease-North American Region, 29 February 2008, San Diego, CA, USA. Vancouver, BC, Canada: British Columbia Lung Association, 2008. http://www.bc.lung.ca/lungdiseases/iuatld-pdfs/2008/ Health-System-Reform-and-Political-Will-Do-These-Interventions-Enable-Reduction- in-TB-Burden.pdf Accessed May 2009.
4. Gourevitch M N, Alcabes P, Wasserman W C, Arno P S. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 531-540. (Pubitemid 28320059)
5. Bell J C, Rose D N, Sacks H S. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS 1999; 13: 1549-1556. (Pubitemid 29396688)
6. Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T. Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 2006; 27: 442-448. (Pubitemid 43835524)
7. Secretaria de Salud. Salud Mexico: 2004. Mexico City, Mexico: Direccion General de Evaluacion y Desempeño, 2005.
8. Centro Nacional para la Prevención y el Control del VIH/SIDA, Consejo Nacional para la Prevencion y Control del VIH/SIDA (CONASIDA). AIDS by numbers. Mexico City, Mexico: CENSIDA, 2006. http://www.salud.gob.mx/conasida/ estadis/2006/elsidaencifras15nov2006.pdf Accessed March 2008. [Spanish]
9. Tuberculosis Along the US-Mexico Border Work Group, Centers for Disease Control and Prevention. Preventing and controlling tuberculosis along the US-Mexico border. MMWR 2001; 50 (RR-1): 1-27.
10. Snyder D C, Paz E A, Mohle-Boetani J C, Fallstad R, Black R L, Chin D P. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness. Am J Respir Crit Care Med 1999; 160: 178-185. (Pubitemid 29326085)
11. Tulsky J P, Hahn J A, Long H L, et al. Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis 2004; 8: 83-91.
12. Figueroa-Munoz J, Ramon-Pardo P. Tuberculosis control in vulnerable groups. Bull World Health Organ 2008; 86: 657-736.
13. ISESALUD. Modificacion de la Norma Oficial Mexicana NOM-006-SSA-1993. Mexico City, Mexico: ISESALUD, 1993: pp 3-10.
14. Diel R, Nienhaus A, Lange C, Meywald-Walter K, Forssbohm M, Schaberg T. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res 2006; 7: 77. (Pubitemid 43959902)
15. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26. (Pubitemid 46101841)
16. Garfein R S. Screening and diagnosis for TB among populations at risk for HIV infection in Tijuana, Mexico. 12th Annual Conference of the International Union Against Tuberculosis and Lung Disease-North American Region, 29 February 2008, San Diego, CA, USA. Vancouver, BC, Canada: British Columbia Lung Association, 2008. http://www.bc.lung.ca/lungdiseases/iuatld-pdfs/2008/PREVE-TB- USAID-UC-San-Diego.pdf Accessed May 2009.
17. Catanzaro A, Perry S, Clarridge J E, et al. The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. JAMA 2000; 283: 639-645. (Pubitemid 30069180)
18. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49 (RR-6): 1-51.
19. Vargas M, Rios L, Salazar M A, Cano F. Costos de atencion de la tuberculosis: caso del Instituto Nacional de Enfermedades Respiratorias (INER). Rev Inst Nal Enf Resp Mex 2003; 16: 219-225. [Spanish]
20. IDA Foundation. Price indicator. Amsterdam, The Netherlands: IDA Foundation, 2007.
21. Comstock G W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? [Counterpoint] Int J Tuberc Lung Dis 1999; 3: 847-850.
22. Efficacy of various durations of isoniazid preventive therapy for tuberculosis 5 years of follow-up in the International Union Against Tuberculosis trial. Bull World Health Organ 1982; 60: 555-564.
23. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-γ-based assay using new antigens. Am J Respir Crit Care Med 2004; 170: 59-64. (Pubitemid 38997752)
24. Strathdee S A, Magis-Rodriguez C. Mexico's evolving HIV epidemic. JAMA 2008; 300: 571-573.
25. Nolan C M, Goldberg S V, Buskin S E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018.
26. Vlahov D, Wang C, Ompad D, et al. Mortality risk among recent-onset injection drug users in five US cities. Subst Use Misuse 2008; 43: 413-428.
27. Mahaparra P, Salomon J A, Nanda L. Measuring health state values in developing countries - results from a community survey in Andhra Pradesh. In: Murray C J, Salomon J A, Murray J A, et al., eds. Summary measures of population health: concepts, ethics, measurement and applications. Geneva Switzerland: World Health Organization, 2002: pp 473-485.
28. Dye C, Scheele S, Dolin P, Pathania V, et al. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. JAMA 1999; 282: 677-686. (Pubitemid 29384157)
29. Scott G. Towards a consistent payer perspective: a microeconomic approach to economic evaluation. Annual meeting of the Economics of Population Health: Inaugural Conference of the American Society of Health Economists, 4 June 2006. Madison, WI, USA: All Academic, 2006.
30. Gold M R. Standardizing cost-effectiveness analyses: the panel on cost-effectiveness in health and medicine. Acad Radiol 1998; 5 (Suppl 2): S351-S354. (Pubitemid 28406435)
31. Drummond M F, Sculpher M J, Torrance G W, O'Brien B J, Stoddart G L. Methods for the economic evaluation of health care programmes. Oxford, UK: Oxford University Press, 2005.
32. Baltussen R, Adam T, Torres T T. Making choices in health. WHO guide to cost-effectiveness analysis. Geneva, Switzerland: World Health Organization, 2003. http://uclibs.org/PID/130450/10062367 Accessed October 2008.
33. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409. (Pubitemid 28140699)
34. Michael V M, Ashley B C, Nichol M E, Thomas J F, Michael J G, Leif I S. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med 2006; 31: 52-61.
35. Radilla-Chavez P, Laniado-Laborin R. Results of directly observed treatment for tuberculosis in Ensenada, Mexico: not all DOTS programs are created equally. Int J Tuberc Lung Dis 2007; 11: 289-292. (Pubitemid 46447436)